Clinical trials: Parkinson Disease (PD)
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Pivotal Study in Advanced Parkinsons Disease Patients
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined)…
- Trial name
- NCT00466167
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 76 sites in Austria, Czechia and 12 more
- Volunteers
- 517 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with…
- Trial name
- NCT04875962
- Testing
- UCB0599
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson Disease
Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease
This study has three objectives about persons with Parkinson's Disease during bicycling: 1. Determine the effect of visual feedback and competition during virtual bicycling on neuromuscular and cardiovascular intensity 2.
- Trial name
- NCT05160025
- Testing
- Virtual reality bicycling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Rutgers, The State University of New Jersey
Parkinson's Disease
Vaccination Uptake (VAX) in PD
This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate vaccinations in people with advanced Parkinson's…
- Trial name
- VAX-PD (NCT02874274)
- Testing
- Standard of Care, Home Visit Program (HVP)
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- NYU Langone Health
Parkinson Disease
PD-Ballet: Effectiveness and Implementation in Parkinson's Disease
Current literature consistently demonstrates beneficial motor effects of dance-based therapies in Parkinson's disease, along with improved quality of life. Little is known about the non-motor gains following such therapy.
- Trial name
- NCT04719468
- Testing
- Dance with ballet elements
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- King's College Hospital NHS Trust
Parkinson Disease
Parkinson's Research: The Organized Genetics Initiative
The purpose of this trial is to study genetic and other risk factors that may be important in the development of Parkinson's disease.
- Trial name
- PROGENI (NCT00086073)
- Where
- 58 sites in United States, Canada and 1 more
- Volunteers
- 1,800 people
- Sponsor
- Indiana University
Parkinson Disease
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease.
- Trial name
- NCT00404170
- Testing
- B-CIT and SPECT imaging
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson Disease (PD)
Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs
Parkinson's disease (PD) is a progressive neurological condition that can affect movement, balance, endurance, and overall quality of life.
- Trial name
- NCT07221266
- Testing
- Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Texas, El Paso
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinsons Disease (PD)
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Parkinson's disease (PD) is currently the fastest-growing neurological condition globally. It is projected to affect 172,000 people in the UK by 2030,with the current annual cost to the country being ~£3.6 billion.
- Trial name
- EJS ACT-PD (NCT07207057)
- Testing
- Telmisartan, Terazosin (Hytrin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- University College, London
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device's (IACD's) on Freezing and Gait in People With Parkinson's Disease (PD)
The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial.
- Trial name
- NCT00727467
- Testing
- Auditory Cueing Device
- Where
- 3 sites in Ireland
- Volunteers
- 47 people
- Sponsor
- University of Dublin, Trinity College
Insomnia Related to Specified Disorder, Parkinson Disease
Computerized Cognitive Behavioral Therapy Trial for Insomnia in Parkinson Disease
The therapeutic options are limited in Parkinson's Disease (PD) patients with insomnia and are often based on pharmacological treatments.
- Trial name
- ACCORD-PD (NCT03041389)
- Testing
- CCBT-I Group, Control Group
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
Urothelial Cancer
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy.
- Trial name
- NCT02335424
- Testing
- pembrolizumab
- Volunteers
- 374 people
- Sponsor
- Merck Sharp & Dohme LLC
Excessive Daytime Sleepiness, Parkinson's Disease
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients
- Trial name
- NCT00642928
- Testing
- BF 2.649 5 mg, BF 2.649 10 mg, BF 2.649 20 mg
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Bioprojet
Movement Disorders
Retrospective Study on MR Imaging of ET and PD Patients Subjected With MRgFUS Thalamotomy
The technological advance of magnetic resonance-guided focused ultrasound (MRgFUS) has once again brought lesion therapy back to the clinical frontline for the treatment of movement disorder.
- Trial name
- NCT04570046
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Deep Brain Stimulation, Parkinson's Disease and Parkinsonism
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however…
- Conditions
- Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
- Trial name
- NCT06914466
- Testing
- Deep Brain Stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.